** Shares of eye-disease focused Eyenovia EYEN.O fall 2.4% to $1.63 premarket
** Co says it is exploring a reverse merger with privately held Betaliq to combine their eye-disease focused operations
** The proposed deal values Betaliq at around $77 million and Eyenovia at about $15 million
** EYEN will hold 16.3% of the combined company and Betaliq will hold the remaining stake, if merger is successful
** Both EYEN's Optejet device and Betaliq's EyeSol technology are used to deliver FDA-approved eye-care medications to patients
** Up to last close, EYEN fell ~2x in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。